Immunodeficiencies

ABSTRACT: Primary immunodeficiencies (PIDs) are uncommon, chronic and severe disorders of the immune system in which patients cannot mount a sufficiently protective immune response, leading to an increased susceptibility to infections. The treatment of choice for PID patients with predominant antibo...

Full description

Autores:
Franco Restrepo, José Luis
Ballow, M.
Grimbacher, B.
Cunningham-Rundles, C.
Notarangelo, L.
Stein, M.
Helbert, M.
Gathmann, B.
Kindle, G.
Knight, A. K.
Ochs, H. D.
Sullivan, K.
Tipo de recurso:
Review article
Fecha de publicación:
2009
Institución:
Universidad de Antioquia
Repositorio:
Repositorio UdeA
Idioma:
eng
OAI Identifier:
oai:bibliotecadigital.udea.edu.co:10495/33048
Acceso en línea:
https://hdl.handle.net/10495/33048
Palabra clave:
Anticuerpos Antibacterianos
Antibodies, Bacterial
Inmunodeficiencia Variable Común
Common Variable Immunodeficiency
Infecciones Bacterianas
Bacterial Infections
Bases de Datos Factuales
Databases, Factual
Inmunoglobulinas Intravenosas
Immunoglobulins, Intravenous
Síndromes de Inmunodeficiencia
Immunologic Deficiency Syndromes
Sistema de Registros
Registries
Infecciones Oportunistas
Opportunistic Infections
Rights
openAccess
License
http://creativecommons.org/licenses/by-nc-nd/2.5/co/
id UDEA2_d3f388fc9f0c8addd978b06b37b43579
oai_identifier_str oai:bibliotecadigital.udea.edu.co:10495/33048
network_acronym_str UDEA2
network_name_str Repositorio UdeA
repository_id_str
dc.title.spa.fl_str_mv Immunodeficiencies
title Immunodeficiencies
spellingShingle Immunodeficiencies
Anticuerpos Antibacterianos
Antibodies, Bacterial
Inmunodeficiencia Variable Común
Common Variable Immunodeficiency
Infecciones Bacterianas
Bacterial Infections
Bases de Datos Factuales
Databases, Factual
Inmunoglobulinas Intravenosas
Immunoglobulins, Intravenous
Síndromes de Inmunodeficiencia
Immunologic Deficiency Syndromes
Sistema de Registros
Registries
Infecciones Oportunistas
Opportunistic Infections
title_short Immunodeficiencies
title_full Immunodeficiencies
title_fullStr Immunodeficiencies
title_full_unstemmed Immunodeficiencies
title_sort Immunodeficiencies
dc.creator.fl_str_mv Franco Restrepo, José Luis
Ballow, M.
Grimbacher, B.
Cunningham-Rundles, C.
Notarangelo, L.
Stein, M.
Helbert, M.
Gathmann, B.
Kindle, G.
Knight, A. K.
Ochs, H. D.
Sullivan, K.
dc.contributor.author.none.fl_str_mv Franco Restrepo, José Luis
Ballow, M.
Grimbacher, B.
Cunningham-Rundles, C.
Notarangelo, L.
Stein, M.
Helbert, M.
Gathmann, B.
Kindle, G.
Knight, A. K.
Ochs, H. D.
Sullivan, K.
dc.subject.decs.none.fl_str_mv Anticuerpos Antibacterianos
Antibodies, Bacterial
Inmunodeficiencia Variable Común
Common Variable Immunodeficiency
Infecciones Bacterianas
Bacterial Infections
Bases de Datos Factuales
Databases, Factual
Inmunoglobulinas Intravenosas
Immunoglobulins, Intravenous
Síndromes de Inmunodeficiencia
Immunologic Deficiency Syndromes
Sistema de Registros
Registries
Infecciones Oportunistas
Opportunistic Infections
topic Anticuerpos Antibacterianos
Antibodies, Bacterial
Inmunodeficiencia Variable Común
Common Variable Immunodeficiency
Infecciones Bacterianas
Bacterial Infections
Bases de Datos Factuales
Databases, Factual
Inmunoglobulinas Intravenosas
Immunoglobulins, Intravenous
Síndromes de Inmunodeficiencia
Immunologic Deficiency Syndromes
Sistema de Registros
Registries
Infecciones Oportunistas
Opportunistic Infections
description ABSTRACT: Primary immunodeficiencies (PIDs) are uncommon, chronic and severe disorders of the immune system in which patients cannot mount a sufficiently protective immune response, leading to an increased susceptibility to infections. The treatment of choice for PID patients with predominant antibody deficiency is intravenous immunoglobulin (Ig) replacement therapy. Despite major advances over the last 20 years in the molecular characterization of PIDs, many patients remain undiagnosed or are diagnosed too late, with severe consequences. Various strategies to ensure timely diagnosis of PIDs are in place, and novel approaches are being developed. In recent years, several patient registries have been established. Such registries shed light on the pathology and natural history of these varied disorders. Analyses of the registry data may also reveal which patients are likely to respond well to higher Ig infusion rates and may help to determine the optimal dosing of Ig products. Faster infusion rates may lead to improved convenience for patients and thus increase patient compliance, and may reduce nursing time and the need for hospital resources. Data from two recent studies suggest that Gamunex® and Privigen® are well tolerated at high infusion rates. Nevertheless, careful selection of patients for high infusion rates, based on co-morbid conditions and tolerance of the current infusion rate, is advisable. Based on the available data, intravenous Ig offers broad protection against encapsulated organisms. As vaccine trends change, careful monitoring of specific antibody levels in the general population, such as those against pneumococcal and meningococcal bacteria, should be implemented.
publishDate 2009
dc.date.issued.none.fl_str_mv 2009
dc.date.accessioned.none.fl_str_mv 2022-12-27T12:56:27Z
dc.date.available.none.fl_str_mv 2022-12-27T12:56:27Z
dc.type.spa.fl_str_mv info:eu-repo/semantics/article
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversion.fl_str_mv http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.hasversion.spa.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.coar.spa.fl_str_mv http://purl.org/coar/resource_type/c_dcae04bc
dc.type.redcol.spa.fl_str_mv https://purl.org/redcol/resource_type/ARTREV
dc.type.local.spa.fl_str_mv Artículo de revisión
format http://purl.org/coar/resource_type/c_dcae04bc
status_str publishedVersion
dc.identifier.citation.spa.fl_str_mv Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, Gathmann B, Kindle G, Knight AK, Ochs HD, Sullivan K, Franco JL. Immunodeficiencies. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):14-22. doi: 10.1111/j.1365-2249.2009.04023.x.
dc.identifier.issn.none.fl_str_mv 0009-9104
dc.identifier.uri.none.fl_str_mv https://hdl.handle.net/10495/33048
dc.identifier.doi.none.fl_str_mv 10.1111/j.1365-2249.2009.04023.x.
dc.identifier.eissn.none.fl_str_mv 1365-2249
identifier_str_mv Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, Gathmann B, Kindle G, Knight AK, Ochs HD, Sullivan K, Franco JL. Immunodeficiencies. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):14-22. doi: 10.1111/j.1365-2249.2009.04023.x.
0009-9104
10.1111/j.1365-2249.2009.04023.x.
1365-2249
url https://hdl.handle.net/10495/33048
dc.language.iso.spa.fl_str_mv eng
language eng
dc.relation.ispartofjournalabbrev.spa.fl_str_mv Clin Exp Immunol
dc.rights.spa.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
dc.rights.accessrights.spa.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.creativecommons.spa.fl_str_mv https://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-nd/2.5/co/
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.format.extent.spa.fl_str_mv 9
dc.format.mimetype.spa.fl_str_mv application/pdf
dc.publisher.spa.fl_str_mv British Society for Immunology
dc.publisher.group.spa.fl_str_mv Inmunodeficiencias Primarias
dc.publisher.place.spa.fl_str_mv Oxford, Inglaterra
institution Universidad de Antioquia
bitstream.url.fl_str_mv https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/2/license_rdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/1/FrancoJose_2009_Immunodeficiencies.pdf
https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/3/license.txt
bitstream.checksum.fl_str_mv b88b088d9957e670ce3b3fbe2eedbc13
e54f4411565e008969dc345add65045e
8a4605be74aa9ea9d79846c1fba20a33
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio Institucional Universidad de Antioquia
repository.mail.fl_str_mv andres.perez@udea.edu.co
_version_ 1805390145444118528
spelling Franco Restrepo, José LuisBallow, M.Grimbacher, B.Cunningham-Rundles, C.Notarangelo, L.Stein, M.Helbert, M.Gathmann, B.Kindle, G.Knight, A. K.Ochs, H. D.Sullivan, K.2022-12-27T12:56:27Z2022-12-27T12:56:27Z2009Ballow M, Notarangelo L, Grimbacher B, Cunningham-Rundles C, Stein M, Helbert M, Gathmann B, Kindle G, Knight AK, Ochs HD, Sullivan K, Franco JL. Immunodeficiencies. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):14-22. doi: 10.1111/j.1365-2249.2009.04023.x.0009-9104https://hdl.handle.net/10495/3304810.1111/j.1365-2249.2009.04023.x.1365-2249ABSTRACT: Primary immunodeficiencies (PIDs) are uncommon, chronic and severe disorders of the immune system in which patients cannot mount a sufficiently protective immune response, leading to an increased susceptibility to infections. The treatment of choice for PID patients with predominant antibody deficiency is intravenous immunoglobulin (Ig) replacement therapy. Despite major advances over the last 20 years in the molecular characterization of PIDs, many patients remain undiagnosed or are diagnosed too late, with severe consequences. Various strategies to ensure timely diagnosis of PIDs are in place, and novel approaches are being developed. In recent years, several patient registries have been established. Such registries shed light on the pathology and natural history of these varied disorders. Analyses of the registry data may also reveal which patients are likely to respond well to higher Ig infusion rates and may help to determine the optimal dosing of Ig products. Faster infusion rates may lead to improved convenience for patients and thus increase patient compliance, and may reduce nursing time and the need for hospital resources. Data from two recent studies suggest that Gamunex® and Privigen® are well tolerated at high infusion rates. Nevertheless, careful selection of patients for high infusion rates, based on co-morbid conditions and tolerance of the current infusion rate, is advisable. Based on the available data, intravenous Ig offers broad protection against encapsulated organisms. As vaccine trends change, careful monitoring of specific antibody levels in the general population, such as those against pneumococcal and meningococcal bacteria, should be implemented.COL00124269application/pdfengBritish Society for ImmunologyInmunodeficiencias PrimariasOxford, Inglaterrainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTREVArtículo de revisiónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-nd/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by-nc-nd/4.0/ImmunodeficienciesAnticuerpos AntibacterianosAntibodies, BacterialInmunodeficiencia Variable ComúnCommon Variable ImmunodeficiencyInfecciones BacterianasBacterial InfectionsBases de Datos FactualesDatabases, FactualInmunoglobulinas IntravenosasImmunoglobulins, IntravenousSíndromes de InmunodeficienciaImmunologic Deficiency SyndromesSistema de RegistrosRegistriesInfecciones OportunistasOpportunistic InfectionsClin Exp ImmunolClinical and Experimental Immunology1422158Suplemento 1CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8823https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/2/license_rdfb88b088d9957e670ce3b3fbe2eedbc13MD52ORIGINALFrancoJose_2009_Immunodeficiencies.pdfFrancoJose_2009_Immunodeficiencies.pdfArtículo de revisiónapplication/pdf287691https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/1/FrancoJose_2009_Immunodeficiencies.pdfe54f4411565e008969dc345add65045eMD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstream/10495/33048/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD5310495/33048oai:bibliotecadigital.udea.edu.co:10495/330482022-12-27 12:15:22.745Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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